Skip to main content

Table 1 Characteristics of the subjects in eligible studies

From: A comparison between triplet and doublet chemotherapy in improving the survival of patients with advanced gastric cancer: a systematic review and meta-analysis

StudyNumber ArmsEfficacyAgeSexDisease statusECOG
OSPFSTTPORRMedianRangeMaleLAME0-1≥2
Median months  N%N%N%N%N%
Fluoropyrimidine-based
 Ajani 200579 DTX+Cis+5-FU9.65.9NA435721-8353704672957910001
76 DTX+Cis10.55NA265730-766177117595759901
 Douglass 198446 5-FU+Doxo+MMC29.5NANA3961.032-813576004610030651635
46 Doxo+MMC19NANA295833-783780004610028611839
 Roth 200741 DTX+Cis+5-FU10.4NA4.636.66135-7830732539954110000
38 DTX+Cis11.0NA3.618.45840-70297671831823810000
 Van Cutsem 201589 DTX+Ox+5-FU14.67.6NA46.658NA61690089100879822
79 DTX+Ox8.934.5NA23.159NA51650079100779911
Platinum-based
 Kikuchi K 199032 ADM+5-FU+CisNANANA6NANANANANANANANANANANANA
33 ADM+5-FUNANANA0NANANANANANANANANANANAN
 Park 200845 Cis+Iri+5-FU10.56.2NA425229-70307600451003884716
46 Iri+5-FU10.74.8NA425526-733067004510035781129
 Roth 199961 Epi+Cis+5-FU9.6NANA42.654NA37611222427824393061
61 Epi+5-FU7.1NANA28.656NA42691630408427442956
Anthracyclin-based
 Douglass 198439 5-FU+Doxo+Me5.5NANA2959.543-76287100391003077923
48 5-FU+Me3.3NANA1462.024-793880004810035721328
 Kim 200148 Epi+Cis+5-FU8.5NA4.441.555NA45753557955490610
48 Cis+5-FU7.3NA3.937.756NA42703557955388712
 KRGCGC 199225 Epi+Cis+5-FU6.9NANA2755NA45753557975490610
22 Cis+5-FU4NANA2455NA45753557955490610
 Yun 201044 Epi+Cis+CapNA6.5NA375537-512864NANANANA409119
47 Cis+CapNA6.4NA385833-753472NANANANA4187413
MMC-based
 Cullinan 198551 5-FU+Doxo+MMCNANANA38.560NA39762039316132631937
49 Doxo+5-FUNANANA27.763NA37761837316333671633
 Koizumi 200433 5-DFUR+Cis+MMC8.03NANA255836-791958NANANANA16481339
29 5-DFUR+Cis5.97NANA17.25837-791759NANANANA2586624
Taxane-based
 AI-Batran 201379 DTX+Ox+5-FU17.39.1NA48.66965-81517122315069679357
76 Ox+5-FU14.57.1NA28.177065-82456322324968659269
 Van Cutsem 2006227 DTX+Cis+5-FU9.2NA5.6375526-791597263213962189931
230 Cis+5-FU8.6NA3.7255525-761587163217972119931
 Wang 2015119 DTX+Cis+5-FU10.27.2NA48.756.619-808168.13025.28977.411596.643.4
115 Cis+5-FU8.54.9NA33.955.533-748876.52622.68974.810893.976.1
 Yamada 2018370 S-1+Cis15.36.5NA56NANANANANANANANANANANANA
371 S-1+Cis+DOC14.27.4NA59.3NANANANANANANANANANANANA
Irinotecan-based
 Guimbaud 2014209 Epi+Cis+Cape9.55.3NA39.261.428-8415474361717383169813617
207 5-FU+Iri9.75.8NA37.861.429-8015575311517685173842713
 Lin 200913 5-FU+Ox+PTXNANANA62.55536-671872NANANANANANANANA
12 5-FU+IriNANANA33.35536-671872NANANANANANANANA
Other
 Kim 1993110 5-FU+Doxo+MMC6.843NA255419-776862NANANANA75682321
112 Cis+5-FU8.615.5NA515120-687163NANANANA83742018
 Li 201150 PTX+Cis+5-FU10.8NANA485920-74326822462856NANANANA
44 Ox+5-FU9.9NANA45.55820-75317017412761NANANANA
 Maiello 201136 Epi+Cis+CapNANANA54.35839-742260NANANANANANANANA
31 DTX+5-FUNANANA22.66144-752374NANANANANANANANA
 Roth 200740 Epi+Cis+5-FU8.3NA4.9255932-71307571733834010000
41 DTX+Cis+5-FU10.4NA4.936.66135-783073253995411000
 Thuss-Patience 200545 Epi+Cis+5-FU9.7NA5.535.66333-753680124498449812
45 DTX+5-FU9.5NA5.337.86234-752964124498429524
 Van Hoefer 2000133 5-FU+Doxo+MTX6.73.3NA125830-749672221711183117881612
134 Cis+5-FU7.24.1NA205724-749168211611384114852015
132 Eto+5-FU+LV7.23.3NA95925-74906822171108312092129
  1. OS Overall survival, PFS Progression-free survival, TTP Time to progression, ORR Objective response rate, LA Locally advanced, ME Metastatic disease, ECOGE Eastern Cooperative Oncology Group performance status, NA Not applicable, DTX Docetaxel, DOC Docetaxel, PTX Palictaxel,Ciscisplatin, 5- FU Fluorouracil, Cape Capcapecitabine, Cap Capcapecitabine, 5-DFUR Doxifluridine, Ox Oxaliplatin, Doxo Doxorubicin, Epi Epirubicin, Iri Irinotecan, MMC Mitomycin C, Eto Etoposide, Cis Cisplatin, ADM Adriamycin, Me Methyl-CCNU, S-1 Tegafur